HCM
GILD icon

Hollencrest Capital Management’s Gilead Sciences GILD Stock Holding History

Hollencrest Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$12.3K – 1254
2025
Q4 		$12.3K Sell
100
-200
-67% -$24.3K ﹤0.01% 787
2025
Q3 		$33.3K Buy
+300
New +$34.1K ﹤0.01% 620

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hollencrest Capital Management's GILD Position: Q2 2026 in Review

Hollencrest Capital Management reduced its Gilead Sciences (GILD) stake by 9.5% in Q2 2026, selling an estimated $10.3K and leaving 744 shares worth $94K. The position accounts for 0.01% of the portfolio, ranked #457.

Hollencrest Capital Management first reported a position in GILD in Q4 2013 and has held it in 43 quarters since. The position peaked at $1.15M in Q1 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Hollencrest Capital Management held 744 shares of Gilead Sciences worth $94K as of Q2 2026.
  • Hollencrest Capital Management sold 78 Gilead Sciences shares in Q2 2026, an estimated $10.3K.
  • Gilead Sciences made up 0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #457 holding.
  • Hollencrest Capital Management first reported a position in Gilead Sciences in Q4 2013 and has held it in 43 quarters since.
  • Hollencrest Capital Management's Gilead Sciences position peaked at $1.15M in Q1 2015.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.